# Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

> **NCT00477971** · PHASE3 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 89 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** dexamethasone
- **DRUG:** melphalan
- **PROCEDURE:** autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00477971
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2012-07
- **Final completion:** 2014-12
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2016-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00477971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00477971, "Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00477971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*